News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment interruptions news

Show

From To
Side-effects
Asthma drug provides effective treatment for immune reconstitution inflammatory syndrome

A drug normally used to treat asthma provided an effective treatment for antiretroviral-associated immune reconstitution inflammatory syndrome, investigators from one of London’s leading HIV treatment

Published
31 January 2007
By
Michael Carter
Changing treatment
One-in-six interrupt treatment within two years of initiating ART

CD4 count-guided treatment interruptions as a long-term HIV treatment strategy have been extensively discussed in recent months, after the early discontinuation of the SMART study

Published
18 September 2006
By
Edwin J. Bernard
Treatment interruptions
SMART study - treatment breaks lower quality of life

HIV-positive individuals in the SMART study who were in the treatment conservation arm experienced a significant decline in quality of life as the study progressed,

Published
28 August 2006
By
Michael Carter
Treatment interruptions
New data shed light on poor outcome in SMART study

In the recently discontinued SMART study, opportunistic illnesses and death occurred more often in participants with higher CD4 cell counts and lower viral loads, according

Published
17 August 2006
By
Liz Highleyman
Treatment interruptions
Staccato study suggests that some CD4-guided treatment interruptions can be safe

The results of the Staccato study, published in the August 5th edition of The Lancet, have demonstrated that CD4-guided treatment interruptions may be safe under

Published
08 August 2006
By
Christopher Gadd
Treatment interruptions
Study concludes that interleukin-2 has no benefit before HIV treatment interruptions, but increases side-effects

Injections of interleukin-2 (Proleukin) do not allow patients to remain off HIV treatment for longer, according to the final results of a randomised controlled trial.

Published
12 June 2006
By
Christopher Gadd
Drug interactions and pharmacokinetics
Variation in gene linked to risk of resistance after stopping efavirenz treatment

Patients with a common genetic mutation are at an elevated risk of developing resistance to efavirenz (Sustiva) after stopping the drug, according to a study

Published
10 April 2006
By
Christopher Gadd
Treatment interruptions
Treatment interruption arm of DART study halted

The treatment interruption arm of a major clinical trial has been terminated after it was found that patients who were randomised to cycles of HIV

Published
15 March 2006
By
Michael Carter
Resistance
CROI: Low rates of resistance seen in Staccato trial of CD4-guided treatment interruptions

Few patients enrolled in the Staccato study examining CD4 cell count-guided treatment interruptions had evidence of resistance mutations in their HIV, according to a poster

Published
27 February 2006
By
Christopher Gadd
Treatment interruptions
CROI News Feature: Experts divided over the future of treatment interruptions

Experts at the Thirteenth Conference on Retroviruses and Opportunistic Infections, held this week in Denver, were divided over the future of structured treatment interruptions during

Published
10 February 2006
By
Edwin J. Bernard
← Prev1...56789...10Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.